Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
07/2000
07/27/2000WO2000027875A3 Activity dependent neurotrophic factor iii (adnf iii)
07/27/2000WO2000023618B1 Polymorphism in a tgf-beta gene correlated to osteoporosis
07/27/2000WO2000023588A3 G-protein coupled receptors
07/27/2000WO2000023096A3 Combination therapy with vip antagonist
07/27/2000WO2000023094A3 Methods of inhibiting platelet activation and recruitment
07/27/2000WO2000022001A8 A potassium channel of the erg family
07/27/2000WO2000021553A3 Method of regulating smn gene expression
07/27/2000WO2000021550A3 Methods and compositions for treating neurodegenerative diseases
07/27/2000WO2000018915A3 Membrane-associated organizational proteins
07/27/2000WO2000018232A8 Method of treatment of cardiovascular injuries
07/27/2000WO2000017375A3 Method to treat haemophilia by in vivo gene therapy with retroviral vectors
07/27/2000WO2000017328A3 Fibrils
07/27/2000WO2000017225A3 A small protein that interacts with a ribonucleotide reductase subunit and uses thereof
07/27/2000WO2000014254A3 Component of bromelain
07/27/2000WO2000012683A9 Stem cells bearing an fgf receptor on the cell surface
07/27/2000WO2000011171A3 Human rna-associated proteins
07/27/2000WO2000005253A9 Antagonists specific for the corticotropin-releasing factor receptor type 2 (crfr2)
07/27/2000WO2000004157A3 Cloning and characterisation of novel mammalian peptidases
07/27/2000WO2000003743A9 Use of inhibitors of prenyltransferases for inhibiting fungal growth
07/27/2000WO1999066944A9 Methods for identifying novel multimeric agents that modulate receptors
07/27/2000WO1999064033A9 Phosphodiesterase-v modulator drugs and their uses
07/27/2000WO1999045116A9 Human homolog of a nuclear migration gene and its use
07/27/2000WO1999036431A9 Compounds with growth hormone releasing properties
07/27/2000WO1999009149A9 Three-dimensional polymer matrices
07/27/2000DE19902550A1 A novel aspartate protease, coding sequence, inhibitors and antibodies, useful for treatment and diagnosis of Alzheimer's disease
07/27/2000CA2627837A1 Pharmaceutical compositions for alleviating discomfort
07/27/2000CA2366844A1 Methods and kits for removing, treating, or preventing lice with driable pediculostatic agents
07/27/2000CA2361276A1 Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation
07/27/2000CA2361272A1 33 human secreted proteins
07/27/2000CA2361138A1 Alpha-conotoxin peptides
07/27/2000CA2361123A1 Methods for identifying, treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
07/27/2000CA2361122A1 Methods and devices for delivery of agents to breast milk ducts
07/27/2000CA2360803A1 Lipophilic quenching of viral inactivating agents
07/27/2000CA2360609A1 Basb055 polynucleotide and polypeptide from neisseria meningitidis. uses thereof
07/27/2000CA2360585A1 Protease
07/27/2000CA2360065A1 Lipoprotein complexes and compositions containing them
07/27/2000CA2360062A1 Baff, inhibitors thereof and their use in the modulation of b-cell response
07/27/2000CA2360058A1 Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
07/27/2000CA2359681A1 Method of treating chronic cardiac disease
07/27/2000CA2359633A1 Homing pro-apoptotic conjugates and methods of using same
07/27/2000CA2359561A1 Proteasome inhibitors
07/27/2000CA2359482A1 Organoprotective solutions
07/27/2000CA2359145A1 Exocytosis pathway proteins and methods of use
07/27/2000CA2359114A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000CA2359113A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000CA2359096A1 Tripeptide compounds useful as selective inhibitors of aminopeptidase a and corresponding pharmaceutical compositions
07/27/2000CA2358971A1 Identifying, monitoring, and treating women for breast precancer or cancer
07/27/2000CA2358963A1 Cancer-associated proteins
07/27/2000CA2358914A1 Polypeptides derived from jnk3
07/27/2000CA2358873A1 Human polypeptide having multiple epidermal growth factor (egf) -like domains, zntr2
07/27/2000CA2358584A1 Method of enhancing needleless transdermal powdered drug delivery
07/27/2000CA2358093A1 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000CA2356681A1 Metalloproteinase-disintegrin family members: svph dnas and polypeptides
07/27/2000CA2356642A1 Improved phytases
07/26/2000EP1022338A2 Viral vaccines
07/26/2000EP1022336A1 POLYPEPTIDE, cDNA ENCODING THE SAME, AND USE OF THEM
07/26/2000EP1022333A1 Human tumor suppressor gene
07/26/2000EP1022286A1 POLYPEPTIDE, cDNA ENCODING THE POLYPEPTIDE, AND USE OF THE BOTH
07/26/2000EP1022268A1 Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
07/26/2000EP1022027A1 Tumor necrosis factor antagonists and their use in endometriosis
07/26/2000EP1021564A1 Process for detecting, extracting or removing human or mammalian cells with a disturbed cellular cycle regulation or unlimited proliferation or tumour-forming ability
07/26/2000EP1021555A1 STABILIZATION OF $i(HELICOBACTER) UREASE
07/26/2000EP1021553A2 Eukaryotic gene expression cassette and uses thereof
07/26/2000EP1021549A2 SENSE mRNA THERAPY
07/26/2000EP1021546A1 Neutral sphingomyelinase
07/26/2000EP1021544A2 Chimeric vaccine against tick-borne encephalitis virus
07/26/2000EP1021543A1 Mutants of yeast cdc24p, defective in binding of the g-protein beta subunit
07/26/2000EP1021542A1 Apo-3 ligand
07/26/2000EP1021541A1 Amino-terminally truncated mcp-2 as chemokine antagonists
07/26/2000EP1021540A1 Human progesterone receptor complex p23-like protein
07/26/2000EP1021539A1 A method for selectively controlling membrane protein display and protein secretion in eukaryotic cells
07/26/2000EP1021537A1 T cell receptor-associated molecules (trams) and methods of use therefor
07/26/2000EP1021535A2 Human cancer antigen ny eso-1/cag-3 and gene encoding same
07/26/2000EP1021534A1 Hepatitis c receptor protein cd81
07/26/2000EP1021533A1 Nucleic acids coding for proteins capable of interacting with presenilins
07/26/2000EP1021464A1 Cellular receptor for hiv-1 vpr essential for g2/m phase transition of the cell cycle
07/26/2000EP1021461A1 Use of neuronal and lymphocytic potassium canal inhibitors for treating neurological diseases of immune origin
07/26/2000EP1021458A1 Helicobacter polypeptides and corresponding polynucleotide molecules
07/26/2000EP1021424A1 Thiadiazole amide mmp inhibitors
07/26/2000EP1021423A1 MACROCYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF$g(a) SECRETION
07/26/2000EP1021209A1 Inactivation of viruses by incubation with caprylate
07/26/2000EP1021202A1 Immunogenic peptides from the hpv e7 protein
07/26/2000EP1021201A1 Use of growth differenciation factor-9 (gdf-9) as a contraceptive
07/26/2000EP1021200A1 Methods and compositions for treating rheumatoid arthritis
07/26/2000EP1021199A1 PEPTIDE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS
07/26/2000EP1021197A1 Implants comprising combinations of allogeneic cells for use in cancer treatment
07/26/2000EP1021190A1 Novel amide derivatives
07/26/2000EP1021169A1 Active agent transport systems
07/26/2000EP1021167A1 High and low load formulations of igf-i in multivesicular liposomes
07/26/2000EP1021134A1 Use of hemoglobin to prevent sepsis or treat systemic inflammatory response syndrome
07/26/2000EP0832134B1 Anti-allergy bispecific molecules
07/26/2000EP0821697B1 Method for preparing streptogramines
07/26/2000EP0769054B1 Immunomodulators
07/26/2000EP0762890B1 Treatment of diabetes
07/26/2000EP0759775B1 Ifn-beta liquid formulations
07/26/2000EP0650374B1 Use of a calcium carbonate based porous material as support for a growth factor in the preparation of a bioabsorbable implant
07/26/2000EP0643583B1 Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy
07/26/2000EP0629293B1 Assay for adrenal autoantibodies
07/26/2000EP0576522B1 A single dose vaccination system
07/26/2000CN1261403A Surface exposed proteins from chlamydia pneumoniae